Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 5.22B 777M 665M 622M 570M 1.07B 74.3B 1.08B 7.35B 2.87B 37.33B 2.92B 2.85B 123B P/E 2026 *
5.46x
P/E 2027 * 4.87x
Enterprise Value 5.22B 777M 665M 622M 570M 1.07B 74.3B 1.08B 7.35B 2.87B 37.33B 2.92B 2.85B 123B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.6x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
3 years 18.53
Extreme 18.53
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 2019-11-30
Comptroller/Controller/Auditor 53 2011-01-31
Director TitleAgeSince
Chairman 70 2002-08-13
Director/Board Member 62 2002-08-13
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-.--% - - 777M
-0.08%-1.43%+15.87%+67.24% 47.71B
-3.21%+1.37%+51.19%+124.26% 40.3B
-0.40%-1.23%-10.08%+17.30% 12.09B
+1.11%-1.34%+13.27%+72.07% 11.68B
+0.19%+0.58%+30.98%+151.21% 9.19B
-0.39%-0.92%+20.49%+39.85% 7.57B
-1.35%+0.74%+47.38%-12.13% 7.24B
-0.64%-0.02%+19.65%+205.39% 6.84B
-5.36%-6.36%-38.04%+19.49% 5.42B
Average -1.12%-1.11%+16.75%+76.07% 16.45B
Weighted average by Cap. -1.14%-0.57%+24.08%+83.63%

Financials

2026 *2027 *
Net sales 3.03B 451M 387M 362M 331M 621M 43.18B 630M 4.27B 1.67B 21.69B 1.69B 1.66B 71.75B 3.26B 485M 416M 389M 356M 668M 46.44B 677M 4.6B 1.79B 23.33B 1.82B 1.78B 77.17B
Net income 956M 142M 122M 114M 104M 196M 13.61B 198M 1.35B 525M 6.83B 534M 522M 22.61B 1.07B 159M 137M 128M 117M 220M 15.26B 222M 1.51B 589M 7.66B 599M 586M 25.35B
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,822
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.911CNY
Average target price
7.943CNY
Spread / Average Target
+14.93%

Quarterly revenue - Rate of surprise